ICON plc (ICLR)
Stock Price Chart
Key Info
| Market Cap | 10.00B |
| Revenue (ttm) | 2.77B |
| Net Income (ttm) | 373.99M |
| Shares Out | 52.63M |
| EPS (ttm) | 6.00 |
| PE Ratio | 31.66 |
| Forward PE | 30.03 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 12, 2020 |
| Last Price | $189.94 |
| Previous Close | $187.90 |
| Change ($) | 2.04 |
| Change (%) | 1.09% |
| Day's Open | 189.71 |
| Day's Range | 188.06 - 191.29 |
| Day's Volume | 146,779 |
| 52-Week Range | 104.28 - 199.83 |
More Stats
| Market Cap | 10.00B |
| Enterprise Value | 9.85B |
| Earnings Date (est) | Oct 21, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 52.63M |
| Float | 51.97M |
| EPS (basic) | 6.85 |
| EPS (diluted) | 6.00 |
| FCF / Share | 6.72 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 3.16% |
| FCF Yield | 3.62% |
| Payout Ratio | n/a |
| Shares Short | 592,066 |
| Short Ratio | 2.26 |
| Short % of Float | 0.98% |
| Beta | 0.86 |
| PE Ratio | 31.66 |
| Forward PE | 30.03 |
| P/FCF Ratio | 27.62 |
| PS Ratio | 3.61 |
| PB Ratio | 6.26 |
| Revenue | 2.77B |
| Operating Income | 433.41M |
| Net Income | 373.99M |
| Free Cash Flow | 361.90M |
| Net Cash | 143.70M |
| Net Cash / Share | 2.73 |
| Gross Margin | 31.11% |
| Operating Margin | 15.64% |
| Profit Margin | 13.30% |
| FCF Margin | 13.06% |
| ROA | 9.11% |
| ROE | 21.59% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,806 | 2,596 | 1,758 | 1,666 | 1,575 | 1,503 | 1,336 | 1,115 | 946 | 900 |
| Revenue Growth | 8.09% | 47.62% | 5.52% | 5.81% | 4.77% | 12.52% | 19.83% | 17.9% | 5.08% | - |
| Gross Profit | 832 | 778 | 731 | 705 | 666 | 600 | 491 | 397 | 334 | 359 |
| Operating Income | 433 | 373 | 338 | 312 | 282 | 202 | 121 | 68.02 | 29.44 | 92.10 |
| Net Income | 374 | 323 | 281 | 262 | 240 | 172 | 103 | 55.42 | 22.88 | 87.07 |
| Shares Outstanding | 53.86 | 54.12 | 54.13 | 55.25 | 58.75 | 61.50 | 60.91 | 59.97 | 60.38 | 59.72 |
| Earnings Per Share | 6.79 | 5.89 | 5.13 | 4.65 | 3.97 | 2.73 | 1.65 | 0.92 | 0.37 | 1.44 |
| EPS Growth | 15.28% | 14.81% | 10.32% | 17.13% | 45.42% | 65.45% | 79.35% | 148.65% | -74.31% | - |
| Operating Cash Flow | 413 | 269 | 383 | 259 | 279 | 169 | 221 | 113 | 20.19 | 87.43 |
| Capital Expenditures | -50.65 | -48.40 | -44.72 | -42.60 | -49.73 | -32.78 | -29.49 | -30.79 | -35.28 | -30.95 |
| Free Cash Flow | 362 | 220 | 338 | 217 | 229 | 136 | 192 | 82.64 | -15.09 | 56.48 |
| Cash & Equivalents | 570 | 456 | 360 | 261 | 190 | 216 | 321 | 190 | 174 | 256 |
| Total Debt | 426 | 349 | 349 | 349 | 348 | - | - | - | - | - |
| Net Cash / Debt | 144 | 106 | 11.56 | -87.92 | -158 | 216 | 321 | 190 | 174 | 256 |
| Assets | 2,908 | 2,354 | 2,147 | 1,826 | 1,717 | 1,529 | 1,442 | 1,202 | 1,028 | 950 |
| Liabilities | 1,250 | 1,000 | 956 | 881 | 954 | 579 | 532 | 448 | 346 | 280 |
| Book Value | 1,618 | 1,354 | 1,191 | 945 | 763 | 950 | 911 | 755 | 682 | 670 |
Company Profile
Company Details
| Full Name | ICON plc |
| Country | Ireland |
| Employees | 15,150 |
| CEO | Stephen A. Cutler |
Stock Information
| Ticker Symbol | ICLR |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: ICLR |
| IPO Date | May 15, 1998 |
Description
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.